IL33 and neoplasm: To maintain focus on the innate immune cell repertoire, we chose to perform these studies in IL-33+ and IL-33− xenografts, a model that allows assessment of the differences in activation states within the tumor immune repertoire, as well as the recruited innate immune cells, such as monocytes and NK cells are reported to be enriched within a glioma tumor environment91–95.